CVBT to Present Disc Ischemia Preliminary Results at World Forum for Spine Research Kyoto Meeting.

LAS VEGAS -- CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) today announced that its investigational study to establish non-invasively the correlation of under-perfusion with disc degeneration has been accepted for presentation by Dr. Vance Gardner at the invitation-only World Forum for Spine Research meeting to be held Jan. 23-26, 2008 in Kyoto, Japan.

CVBT is conducting this investigational study in conjunction with the Orthopaedic Education and Research Institute of Southern California and the University of California, Irvine. Dr. Gardner is the lead investigator and has developed a Magnetic Resonance Imaging technique that images the feeding arteries and measures spinal blood flow into the region. Normal controls as well as patients with low back pain due to degenerative disc disease are being evaluated.

"Our technique is aimed at defining vascular abnormalities that lead to nutritional impairment in patients with degenerative disc disease," said Dr. Gardner. "If a resultant ischemic disc disease patient subset can be defined, improving blood flow through angiogenic therapy may provide a favorable environment for disc regeneration."

The World Forum for Spine Research is an international forum which brings together clinicians, biologists, engineers, and scientists to share knowledge in basic, translational, and clinical research on the intervertebral disc. Dr. Gardner will present his study findings on Jan. 24th at 11:30 AM. The meeting will cover all aspects of the intervertebral disc, from health to disease, and from current to future treatments.

"CVBT is developing additional formulations of FGF-1, a recombinant protein that stimulates new blood vessel growth, a process known as angiogenesis, to serve as a new and cost effective approach for a number of cardiovascular disease indications. The study will provide much needed information for the development of a protocol utilizing FGF-1 to treat hypoxic/ischemic disc disease," said Daniel Montano, Chairman of CVBT.

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has FDA-authorization for a Phase II trial to treat severe Coronary Heart Disease (CVBT-141H) and a Phase I trial to treat Peripheral Arterial Disease (CVBT-141C). A Phase Ib or Phase II trial to treat dermal wound healing in diabetics (CVBT-141B) is planned to begin in the first quarter of 2008.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward-looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.